Rubius Therapeutics is genetically engineering red blood cell therapeutics, or RCTs, to treat a range of diseases. These RCTs are capable of targeting cancer through activating immunity, treating auto-immune diseases through self-antigen tolerance induction, and combating rare enzyme deficiencies by introducing therapeutic enzymes that are cellularly shielded.
Number of employees: 51 – 250
Location: Cambridge, MA, USA
Collaborating with inaccessible data
Manual record keeping systems that housed all experimental data – including donor metadata, DNA stock, and prototype protein expression – were disorganized and cluttered, hindering cross-team collaboration.
Inefficient request fulfillment
Legacy request management protocols were inefficient and required scientists and managers to search through scattered, disparate records on cell cultures and quality control assays.
Difficulty tracking projects
Engineering processes were out of sync and difficult to track as a result of decentralized systems of information storage and unreliable reporting on project progress.